Hypoxic burden to guide CPAP treatment allocation in patients with obstructive sleep apnoea: a
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
17
05
2023
accepted:
27
08
2023
pubmed:
22
9
2023
medline:
22
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
Hypoxic burden (HB) has emerged as a strong predictor of cardiovascular risk in obstructive sleep apnoea (OSA). We aimed to assess the potential of HB to predict the cardiovascular benefit of treating OSA with continuous positive airway pressure (CPAP). This was a The population (362 patients assigned to CPAP and 365 patients assigned to usual care) was middle-aged (mean age 59.7 years), overweight/obese and mostly male (84.5%). A significant interaction was found between the treatment arm and the HB categories. In the high HB group, CPAP treatment was associated with a significant reduction in the incidence of cardiovascular events (HR 0.57, 95% CI 0.34-0.96). In the low HB group, CPAP-treated patients exhibited a trend toward a higher risk of cardiovascular outcomes than those receiving usual care (HR 1.33, 95% CI 0.79-2.25). The differential effect of the treatment depending on the baseline HB level followed a dose-response relationship. In non-sleepy ACS patients with OSA, high HB levels were associated with a long-term protective effect of CPAP on cardiovascular prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Hypoxic burden (HB) has emerged as a strong predictor of cardiovascular risk in obstructive sleep apnoea (OSA). We aimed to assess the potential of HB to predict the cardiovascular benefit of treating OSA with continuous positive airway pressure (CPAP).
METHODS
METHODS
This was a
RESULTS
RESULTS
The population (362 patients assigned to CPAP and 365 patients assigned to usual care) was middle-aged (mean age 59.7 years), overweight/obese and mostly male (84.5%). A significant interaction was found between the treatment arm and the HB categories. In the high HB group, CPAP treatment was associated with a significant reduction in the incidence of cardiovascular events (HR 0.57, 95% CI 0.34-0.96). In the low HB group, CPAP-treated patients exhibited a trend toward a higher risk of cardiovascular outcomes than those receiving usual care (HR 1.33, 95% CI 0.79-2.25). The differential effect of the treatment depending on the baseline HB level followed a dose-response relationship.
CONCLUSION
CONCLUSIONS
In non-sleepy ACS patients with OSA, high HB levels were associated with a long-term protective effect of CPAP on cardiovascular prognosis.
Identifiants
pubmed: 37734857
pii: 13993003.00828-2023
doi: 10.1183/13993003.00828-2023
pmc: PMC10701092
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT01335087']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL153874
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL135818
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: M.Á. Martinez-Garcia received grants from VitalAire and Philips, Spain, and serves as a consultant for ResMed Inc., Australia, companies that develop products related to sleep apnoea. L. Messineo received a consultancy fee from Apnimed. A. Wellman works as a consultant for Apnimed, SomniFix and Nox, and has received grants from SomniFix and Sanofi; A. Wellman has a financial interest in Apnimed, a company developing pharmacological therapies for sleep apnoea. His interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. S. Redline received grant support and consulting fees from Jazz Pharmaceuticals, and consulting fees from Apnimed and Lilly Pharma. S. Sands receives personal fees as a consultant for Nox Medical and Merck, outside the submitted work, and receives grant support from Apnimed and ProSomnus. F. Barbé received a research grant from ResMed Inc., Australia, a company that develops products related to sleep apnoea. A. Azarbarzin reports grant support from SomniFix and serves as a consultant for SomniFix, Respicardia, Eli Lilly and Apnimed. Apnimed is developing pharmacological treatments for obstructive sleep apnoea. A. Azarbarzin's interests were reviewed by Brigham and Women's Hospital and Mass General Brigham in accordance with their institutional policies. All other authors declare no competing interests.
Références
Lancet Respir Med. 2013 Mar;1(1):61-72
pubmed: 24321805
J Inflamm (Lond). 2013 Mar 22;10:13
pubmed: 23518041
Am J Respir Crit Care Med. 2019 Aug 15;200(4):412-413
pubmed: 30916985
JAMA. 2000 Apr 12;283(14):1829-36
pubmed: 10770144
J Clin Sleep Med. 2017 Mar 15;13(3):479-504
pubmed: 28162150
Lancet Respir Med. 2019 Aug;7(8):687-698
pubmed: 31300334
JAMA. 2013 Dec 11;310(22):2407-15
pubmed: 24327037
N Engl J Med. 2016 Sep 8;375(10):919-31
pubmed: 27571048
Am J Respir Crit Care Med. 2016 Nov 15;194(10):1286-1294
pubmed: 27181196
Eur Heart J. 2019 Apr 7;40(14):1149-1157
pubmed: 30376054
Chest. 2020 Aug;158(2):739-750
pubmed: 32298733
Sleep. 2021 Jul 9;44(7):
pubmed: 33693939
Sleep Med Rev. 2020 Aug;52:101312
pubmed: 32248026
Breathe (Sheff). 2019 Mar;15(1):7-10
pubmed: 30838054
Lancet. 2005 Mar 19-25;365(9464):1046-53
pubmed: 15781100
Arch Bronconeumol. 2022 Jan;58(1):52-68
pubmed: 33875282
Chest. 2015 Mar;147(3):708-718
pubmed: 25412159
Thorax. 2020 Jan;75(1):57-63
pubmed: 31439722
Chest. 2019 Sep;156(3):431-437
pubmed: 31075218
Clin Cardiol. 2021 Dec;44(12):1729-1738
pubmed: 34791676
Thorax. 2021 Jul;76(7):704-713
pubmed: 33277428
Respirology. 2015 Aug;20(6):889-95
pubmed: 26073295
Sleep. 2010 Oct;33(10):1373-80
pubmed: 21061860
PLoS Med. 2009 Aug;6(8):e1000132
pubmed: 19688045
Clin Cardiol. 2013 Sep;36(9):495-501
pubmed: 23843147
J Am Coll Cardiol. 2017 Feb 21;69(7):841-858
pubmed: 28209226
Am J Respir Crit Care Med. 2022 Jan 1;205(1):108-117
pubmed: 34648724
JAMA. 2003 May 21;289(19):2554-9
pubmed: 12759327
Am J Respir Crit Care Med. 2016 Sep 1;194(5):613-20
pubmed: 26914592
Am J Respir Crit Care Med. 2007 Oct 1;176(7):706-12
pubmed: 17556718
Arch Bronconeumol. 2023 Jan;59(1):36-43
pubmed: 36115739
N Engl J Med. 2000 May 11;342(19):1378-84
pubmed: 10805822
Sleep. 2008 Nov;31(11):1551-8
pubmed: 19014075
Chest. 2016 Jan;149(1):16-9
pubmed: 26182150
Circulation. 2010 Jul 27;122(4):352-60
pubmed: 20625114
Sleep. 2021 Feb 12;44(2):
pubmed: 33165616
J Sleep Res. 2020 Aug;29(4):e13066
pubmed: 32406974
Breathe (Sheff). 2019 Mar;15(1):11-14
pubmed: 30838055
Thorax. 2006 May;61(5):430-4
pubmed: 16467072
Eur Respir J. 2021 Mar 25;57(3):
pubmed: 33214210
Lancet Respir Med. 2020 Apr;8(4):359-367
pubmed: 31839558
Sleep. 2005 Apr;28(4):472-7
pubmed: 16171292
JAMA. 2015 Dec 1;314(21):2280-93
pubmed: 26624827
Ann Intern Med. 2012 Jan 17;156(2):115-22
pubmed: 22250142
Sleep Med. 2002 Jan;3(1):43-7
pubmed: 14592253
J Am Coll Cardiol. 2021 Aug 10;78(6):608-624
pubmed: 34353537
Ann Am Thorac Soc. 2023 Nov;20(11):1633-1641
pubmed: 37531573